Evicenter
P&T meetings

Bezuclastinib

Gastrointestinal stromal tumor

Manufacturer
Cogent Biosciences
Regulatory submission
NDA submitted April 2026
Last updated
76 sources

Product information and disease descriptionProduct descriptionProduct information

Indication

2 evidence topics · 2 sources

Orphan-designated indication

“Orphan Designation: Treatment of gastrointestinal stromal tumors (GIST)” (opens the source at this quote in a new tab)

Anticipated indication after prior imatinib

“patients with Gastrointestinal Stromal Tumors (GIST) who have received prior treatment with imatinib.” (opens the source at this quote in a new tab)